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Hepatocyte growth factor (HGF) is a potent antifibrotic
protein that inhibits kidney fibrosis through several
mechanisms. To study its role in podocyte homeostasis,
injury, and repair in vivo, we generated conditional knockout
mice in which the HGF receptor, c-met, was specifically
deleted in podocytes using the Cre–LoxP system. Mice with
podocyte-specific ablation of c-met (podo-met/) developed
normally. No albuminuria or overt pathologic lesions were
detected up to 6 months of age, suggesting that HGF
signaling is dispensable for podocyte maturation, survival,
and function under normal physiologic conditions. However,
after adriamycin treatment, podo-met/ mice developed
more severe podocyte injury and albuminuria than their
control littermates. Ablation of c-met also resulted in more
profound suppression of Wilms tumor 1 (WT1) and nephrin
expression, and podocyte apoptosis after injury. When HGF
was expressed ectopically in vivo, it ameliorated adriamycin-
induced albuminuria, preserved WT1 and nephrin expression,
and inhibited podocyte apoptosis. However, exogenous HGF
failed to significantly reduce albuminuria in podo-met/
mice, suggesting that podocyte-specific c-met activation by
HGF confers renal protection. In vitro, HGF was able to
preserve WT1 and nephrin expression in cultured podocytes
after adriamycin treatment. HGF also protected podocytes
from apoptosis induced by a lethal dose of adriamycin
primarily through a phosphoinositide 3-kinase (PI3K)/Akt-
dependent pathway. Collectively, these results indicate that
HGF/c-met signaling has an important role in protecting
podocytes from injury, thereby reducing proteinuria.
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Hepatocyte growth factor (HGF) is a pleiotropic protein that
has an important role in the regulation of organ develop-
ment, tissue homeostasis, injury repair, and regeneration.1,2
Extensive studies have demonstrated that HGF is also a
potent antifibrotic factor that prevents the onset and
progression of a wide variety of chronic kidney diseases,
including diabetic nephropathy, obstructive nephropathy,
remnant kidney after 5/6 renal ablation, and chronic allograft
nephropathy.3–7 Interestingly, administration of HGF protein
or its gene seems particularly effective in ameliorating
proteinuric kidney diseases,8,9 in which podocyte dysfunction
and/or depletion are thought to have a causative role.10–12
These observations suggest a possible linkage of HGF
signaling to podocyte function under physiological and
pathological conditions. However, the function of HGF in
podocyte maturation, survival, and differentiation in vivo in
normal physiologic setting remains poorly understood.
Furthermore, very little is known about the role of HGF in
regulating podocyte dysfunction and survival in vivo after a
variety of insults.
Podocytes are specialized, terminally differentiated visceral
epithelial cells that reside on the glomerular basement
membrane outside the glomerular capillaries.13 These cells
possess unique, sophisticated foot processes, and slit
diaphragm, a membrane-like structure that is one of the
principal components of the glomerular filtration barrier.14
Not surprisingly, disruption of podocyte integrity will lead to
development of proteinuria and glomerulosclerosis. Depend-
ing on the severity and duration of injury, podocytes respond
to various injurious stimuli in different ways, including
dedifferentiation, detachment, and apoptosis.15,16 Emerging
evidence indicates that podocytes also undergo epithelial-to-
mesenchymal transition after injury by losing their unique
features and acquiring mesenchymal markers.17,18 In view of
the ability of HGF in regulating epithelial-to-mesenchymal
transition and cell survival,5,19 it is plausible to speculate that
HGF could have a role in preserving podocyte structure and
function after injury, thereby preventing the development of
proteinuria.
The biological activities of HGF are mediated by a single
receptor, c-met, which belongs to a family of the transmem-
brane tyrosine kinase receptors that transmit growth factor
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signals across the plasma membrane by activating multiple
downstream signaling events.1,20 Although HGF expression is
limited to nonepithelial cells in the kidney, such as
fibroblasts, mesangial cells, and endothelial cells, c-met
protein is ubiquitously expressed in almost all types of
cells.21 Podocytes in normal glomeruli are shown to express
c-met protein,21 suggesting that these cells are capable of
responding to HGF stimulation.
To elucidate the role of HGF/c-met signaling in podocyte
homeostasis and injury/repair in vivo, here we have generated
conditional knockout mice in which c-met is specifically
ablated in podocytes by using Cre–LoxP recombination
system. We show that mice with podocyte-specific deletion
of c-met are healthy but develop more severe albuminuria,
podocyte lesions, and podocyte loss after injury. In addition,
ectopic expression of exogenous HGF ameliorates podocyte
dysfunction and apoptosis and reduces proteinuria. Our
findings suggest that HGF/c-met signaling is critical for
preventing podocyte injury and proteinuria in pathological
conditions.
RESULTS
Mice with podocyte-specific ablation of c-met are healthy
To explore the role of HGF/c-met signaling in podocyte
homeostasis in vivo, we generated conditional knockout mice
in which c-met gene was specifically disrupted in glomerular
podocytes by using the Cre–LoxP system (Figure 1a). Figure
1b shows different genotypes of the mice by PCR analysis of
genomic DNA. Mice with podocyte-specific ablation of c-met
was designated as podo-met/ (genotype: c-metfl/fl, Creþ /;
Figure 1b, lane 2), whereas c-met-floxed mice were used as
podo-metþ /þ controls (genotype: c-metfl/fl, Cre/; Figure
1b, lane 1). Western blot analysis demonstrated that c-met
protein level was reduced in the isolated glomeruli from
podo-met/ mice, compared with those from control podo-
metþ /þ littermates (Figure 1c). Notably, the faint c-met
protein band seen in the western blot analysis of podo-met/
mice (Figure 1c) was probably derived from the nonpodocyte
glomerular cells, as both mesangial and endothelial cells
express c-met protein. There was no difference in body
weight, kidney/body weight ratio, and urine albumin level
between podo-met/ mice and their control littermates at 3
and 6 months after birth, respectively (Figure 1d–f). Podocyte
numbers and density as shown by Wilms tumor 1 (WT1)
staining were similar in podo-met/ mice and their control
littermates. Furthermore, there was no alteration in major
slit-diaphragm protein, nephrin, expression and distribution
in the glomeruli of podo-met/ mice, in comparison with
the control littermates. Electron microscopy showed an intact
ultrastructure of the glomerular filtration barrier in podo-
met/ mice (see below). Together, these results demonstrate
that HGF/c-met signaling seems dispensable for podocyte
maturation, survival, and function under normal physiologic
conditions in vivo.
Ablation of c-met aggravates albuminuria and exacerbates
WT1 and nephrin loss after adriamycin injury
Next, we investigated the role of HGF/c-met signaling in
podocyte injury under pathological conditions by challenging
podo-met/ mice with adriamycin (ADR), an agent that
specifically damages glomerular podocytes.22 As shown in
Figure 2, mice developed albuminuria at day 1 and 3,
respectively, after intravenous injection of ADR at a dose of
25mg/kg body weight. Under same conditions, podo-met/
mice developed more severe albuminuria at day 3, compared
with the control littermates. Sodium dodecyl sulfate–polya-
crylamine gel electrophoresis analysis of urine samples after
normalization to urinary creatinine revealed that albumin
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Figure 1 |Mice with podocyte-specific ablation of c-met are healthy. (a) Experimental design shows the strategy of the crossbreeding of
mice to generate podocyte-specific deletion of c-met receptor. (b) Genotyping of the mice by PCR analysis of genomic DNA. Lane 1,
genotype: c-metfl/fl, Cre/, designated as podo-metþ /þ control; Lane 2, genotype: c-metfl/fl, Creþ /, designated as podo-met/,
podocyte-specific ablation of c-met; Lane 3, genotype: c-metfl/, Cre/; Lane 4, genotype: c-metfl/, Creþ /. (c) Western blot analysis of
glomerular c-met protein in podo-c-met/ mice (c-metfl/fl, Creþ /) and control podo-metþ /þ littermates (c-metfl/fl, Cre/). Glomerular
lysates were prepared from the mice and immunoblotted with antibodies against c-met and a-tubulin, respectively. (d–f) Mice with
podocyte-specific ablation of c-met are phenotypically normal. There was little difference in body weight (d), kidney/body weight index
(e), and urinary albumin excretion (f) between podo-c-met/ mice and their control littermates at different time points (n¼ 4).
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was the major constituent of urine proteins in mice after
ADR injury (Figure 2b).
We further examined the expression of WT1, a nuclear
zinc finger-containing transcription factor, that is a mole-
cular signature of podocytes and has an essential role in
establishing the podocyte-specific gene expression in adult
kidney.23,24 As shown in Figure 3a and b, ADR caused a
significant decrease in the number of the WT1-positive cells
in the glomeruli of podo-metþ /þ mice. Ablation of c-met,
however, markedly exacerbated WT1 loss after ADR injury
(Figure 3a and b). Notably, ablation of c-met not only
reduced the number of WT1-positive cells after ADR injury,
but also significantly decreased the level of WT1 in the
positively stained podocytes (Figure 3a, arrowheads), sug-
gesting the pivotal role of HGF/c-met signaling in preserving
WT1 expression in vivo.
Immunofluorescent staining revealed that levels of
nephrin were reduced and its distribution was changed from
a linear to granular pattern in control podo-metþ /þ mice
after ADR injury (Figure 3a). As illustrated in the enlarged
boxed area, nephrin staining in normal glomeruli exhibited a
typical, fine line pattern in the podocytes (Figure 3a@, arrow).
The ADR-caused injury not only reduced the overall
abundance of nephrin protein, but also converted its linear
staining into a disorganized, scattered, and granular pattern
(Figure 3a*, arrow). These lesions in nephrin expression and
distribution were more severe in podo-met/ mice after
ADR injury, compared with the control littermates (Figure 3a
and c). We also examined the ultrastructure of podocyte foot
processes and slit diaphragm by electron microscopy. As
shown in Figure 3d, foot process effacement was evident and
slit diaphragm disappeared in some area of the glomeruli in
podo-metþ /þ mice after ADR injection. More severe lesions
in the foot processes and slit diaphragm, however, were
observed in podo-met/ mice under the same conditions
(Figure 3d).
Ablation of c-met promotes podocyte apoptosis after injury
In view of a decrease in the WT1-positive cells in the
glomeruli after ADR injury, we next examined whether
podocytes undergo apoptosis. Immunohistochemical stain-
ing for the cleaved caspase-3 revealed that apoptosis was
extremely rare in mice at day 3 after injection of ADR
(Figure 4), a time point when significant albuminuria
developed (Figure 2). Quantitative determination of apopto-
tic cells showed about two apoptotic cells among every 100
glomerular cross-sections (Figure 4e). Judged from their
localization in the glomeruli, these apoptotic cells appeared
to be podocytes (Figure 4c). Interestingly, ablation of
c-met in a podocyte-specific manner increased the numbers
of apoptotic cells in the glomeruli after ADR injection
(Figure 4d and e), suggesting that HGF/c-met signaling has
an important role in podocyte survival after injury.
Expression of exogenous HGF in mice ameliorates podocyte
injury and albuminuria
To confirm the protective role of HGF/c-met signaling in
preserving podocyte function, we sought to evaluate the
effect of exogenous HGF on proteinuric nephropathy in
mice. To this end, BALB/c mice were injected intravenously
with HGF expression plasmid (pCMV-HGF) or empty vector
(pcDNA3) by using a hydrodynamic-based gene delivery
approach. Notably, this method produced substantial exo-
genous HGF in kidney glomeruli and in circulation, as
previously reported.8,25,26 To ascertain that glomerular
podocytes respond to exogenous HGF, we examined the
activation of extracellular signal-regulated kinase-1/2 (Erk-1/2),
a major downstream mediator of HGF signaling. As shown in
Figure 5, HGF plasmid injection induced a marked
phosphorylation of Erk-1/2 in mouse glomeruli. Double
immunostaining revealed that phospho-specific Erk-1/2 was
largely colocalized with nephrin, suggesting a podocyte-
specific response to exogenous HGF expression. We admini-
strated ADR (10mg/kg body weight) into BALB/c mice at
16 h after HGF plasmid injection (Figure 5a). Heavy
albuminuria developed in mice at day 3 and day 4 after
ADR injection (Figure 5c). Interestingly, delivery of exogenous
3
2
1
0
Ur
in
ar
y 
al
bu
m
in
(m
g/m
g U
cr.
)
75
50
Vehicle ADR
Albuimin
1 2 1 2 1 2 1 2M
ar
ke
r
BS
A
0 1 3
Days after ADR
podo-met +/+
po
do
-m
et 
+/+
po
do
-m
et 
–
/–
po
do
-m
et 
+/+
po
do
-m
et 
–
/–
podo-met –/–
*
*
†
Figure 2 |Mice with podocyte-specific ablation of c-met are
more susceptible to the development of albuminuria induced
by adriamycin (ADR). (a) Urinary albumin levels in control and
podo-c-met/ mice after ADR injection (25mg/kg body weight).
*Po0.05 versus vehicle control (day 0); wPo0.05 versus control
podo-metþ /þ mice (n¼ 5–7). (b) Representative sodium dodecyl
sulfate–polyacrylamine gel electrophoresis shows the urinary
proteins after normalization to urinary creatinine (Ucr.) in podo-
metþ /þ and podo-met/ mice as indicated. Urine proteins after
separation were stained with Coomassie blue R-250. BSA, bovine
serum albumin. Numbers (1, 2) indicate each individual animal in
a given group.
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HGF gene markedly ameliorated ADR-induced albuminuria in
these mice (Figure 5c). Consistent with the albuminuria data,
exogenous HGF expression also prevented a reduction of WT1
and nephrin expression induced by ADR. As shown in
Figure 5d and e, ADR caused significant loss of WT1
expression in glomerular podocytes; and HGF expression
almost completely preserved WT1 protein expression. Simi-
larly, exogenous HGF also preserved nephrin expression and its
distribution in podocytes after ADR injury (Figure 5d and f).
To assess whether the beneficial effect of exogenous
HGF is directly related to c-met activation in podocytes,
we examined the reno-protective role of exogenous HGF in
podo-met/ mice after ADR injury. As shown in Figure 5g,
although ectopic expression of exogenous HGF reduced
albuminuria in podo-metþ /þ mice after ADR injection, it
did not significantly affect albuminuria in podo-met/ mice
in which c-met was specifically ablated in podocytes,
suggesting a direct and predominant role of podocyte-
specific c-met signaling in conferring HGF renoprotection
after ADR injury.
Figure 6 shows the effect of exogenous HGF on podocyte
apoptosis induced by ADR. Glomerular cell apoptosis was
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Figure 3 |Ablation of c-met receptor aggravates podocyte injury induced by adriamycin (ADR). (a) Immunohistochemical staining for
Wilm’s tumor 1 (WT1) and nephrin in different groups as indicated. Arrows indicate WT1-positive cells in the glomeruli. Arrowheads denote
weak staining for WT1 in the glomeruli after ADR injection (25mg/kg body weight). Boxed areas were enlarged to show the distribution
pattern of nephrin in control and ADR-treated glomeruli. A fine, linear nephrin staining pattern was observed in normal glomeruli (@),
whereas a disorganized, granular staining was observed after ADR injection (*). (b) Quantitative determination of WT1-positive cells in the
glomeruli in different groups as indicated. Data are expressed as WT1-positive cells per glomerular cross-section. (c) Semi-quantitative
determination of podocyte injury score (as defined by nephrin loss and altered distribution) in different groups. *Po0.05 versus vehicle
treatment (n¼ 4–11). wPo0.05 versus control podo-metþ /þ mice after ADR (n¼ 11). (d) Electron microscopy (EM) shows the ultrastructure
of glomerular filtration apparatus in different groups. Representative EM pictures demonstrate podocyte foot process effacement (arrows)
and altered glomerular basement membrane (arrowhead) after ADR injection.
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also detectable, albeit extremely rare, in BALB/c mice after
ADR injection. The incidence of apoptosis was about two
cells per 100 glomerular cross-sections (Figure 6d). Delivery
of exogenous HGF gene almost completely prevented
glomerular cells from apoptosis induced by ADR in vivo
(Figure 6c and d).
HGF preserves WT1 and nephrin expression in podocytes
after injury in vitro
To further investigate HGF protection of podocytes from
injury, we used cultured mouse podocytes as an in vitro
system. As shown in Figure 7a and b, incubation of mouse
podocytes with a sub-lethal dose of ADR (2 mg/ml) for 16 h
markedly downregulated WT1 protein expression. Although
HGF alone had little effect on WT1 expression, simultaneous
incubation with it largely preserved WT1 protein expression
after ADR treatment in a dose-dependent manner (Figure 7a
and b).
We then examined the expression of nephrin, a major
slit diaphragm-associated protein, which is a direct tran-
scriptional target of WT1.27,28 In cultured podocytes,
nephrin mRNA expression was suppressed after ADR
treatment (Figure 7c and d). HGF alone seemed to have
the tendency to slightly downregulate nephrin mRNA
expression. Simultaneous incubation with HGF, however,
clearly preserved nephrin mRNA expression in ADR-treated
podocytes (Figure 7c and d).
HGF prevents podocyte apoptosis after injury in vitro
We also examined the ability of HGF in protecting podocytes
from apoptosis after injury in vitro. When mouse podocytes
were incubated with a lethal dose of ADR (20 mg/ml), these
cells underwent apoptosis in a time-dependent manner,
characterized by caspase-3 cleavage and activation (Figure 8a).
Treatment of the cells with HGF largely prevented caspase-3
cleavage induced by ADR. The antiapoptotic activity of HGF
was also dose dependent (Figure 8b). Similar pro-survival
action of HGF was found in cultured human podocytes as
well (Figure 8c and d). Terminal deoxynucleotidyl transfer-
ase-mediated dUTP nick-end labeling and immunostaining
for cleaved caspase-3 also confirmed the cytoprotective
ability of HGF in podocytes after a lethal dose of ADR
(Figure 9).
We next investigated the potential signal pathway leading
to HGF protection of podocytes. As shown in Figure 10a
and b, HGF markedly and rapidly activated protein kinase B/
Akt and mitogen-activated protein kinase Erk-1/2 phosphory-
lation and activation. Incubation with wortmannin, a specific
inhibitor of Akt upstream phosphoinositide 3-kinase (PI3K),
or PD98058, a specific inhibitor of Erk-1/2 upstream Mek1,
blocked Akt and Erk-1/2 phosphorylation, respectively
(Figure 10a and b). As shown in Figure 10c and d, blockade
of Akt activation by wortmannin, but not Erk-1/2 activation
by PD98059, abolished the ability of HGF to prevent
podocyte apoptosis induced by ADR, suggesting that HGF
promotes podocyte survival through a PI3K/Akt-dependent
pathway.
DISCUSSION
Podocyte dysfunction and depletion are increasingly recog-
nized as causative events in the pathogenesis of proteinuria
and glomerulosclerosis in many common forms of protei-
nuric kidney diseases, such as diabetic nephropathy and focal
and segmental glomerulosclerosis.10,16,29 In this context,
identification of crucial factors that regulate podocyte
survival, differentiation, function, and injury/repair will be
of vital importance in understanding the mechanism under-
lying the onset of proteinuria, and in exploring new
therapeutic strategies. In this study, we demonstrate that
HGF/c-met signaling has a critical role in preventing
podocyte injury under pathologic conditions. The ablation
of HGF signaling in podocytes by conditional knockout of its
c-met receptor renders the mice more susceptible to
ADR-induced podocyte injury, resulting in more severe
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Figure 4 |Glomerular cells are more susceptible to apoptosis
in mice with podocyte-specific ablation of c-met.
Immunohistochemical staining reveals the cleaved caspase-3-
positive cells in glomeruli. (a–d) Representative micrographs show
the cleaved caspase-3-positive glomerular cells in control or
podo-met/ mice after injection with vehicle (a and b) or
adriamycin (ADR) (c and d) (25mg/kg body weight). (e)
Quantitative determination of the cleaved caspase-3-positive
glomerular cells in different groups as indicated. Data are
presented as cleaved caspase-3-positive cells per 100 glomerular
cross-sections. *Po0.05 versus vehicle controls, wPo0.05 versus
control podo-metþ /þ mice after ADR injection (n¼ 4–8).
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albuminuria. Conversely, ectopic expression of exogenous
HGF gene in mice protects podocytes and ameliorates
albuminuria in ADR nephropathy. Our findings clearly
establish that HGF/c-met signaling is cytoprotective in
preventing podocyte dysfunction and apoptosis in diseased
kidney.
Despite its expression in podocytes, knockout of c-met
receptor in mice does not result in any overt abnormality in
glomerular structure and function. This suggests that HGF
signaling is dispensable for podocyte maturation, survival,
and function under physiological conditions. Given the
functional redundancy of many peptide growth factors
in vivo,30 it is not completely surprising that mice with
podocyte-specific deletion of c-met receptor have normal
phenotype, with no effect on body and kidney growth, and
on kidney function. This finding is compatible with previous
observation in liver, in which knockout of c-met receptor
specifically in hepatocytes does not cause any detrimental
effect under physiological conditions.31 It is worthwhile to
point out that the Cre recombinase driven under podocin
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Figure 5 | Expression of exogenous hepatocyte growth factor (HGF) protects against podocyte injury and albuminuria induced by
adriamycin (ADR) in mice. (a) Experimental design shows the timing of pCMV-HGF plasmid and ADR injections in BALB/c mice. (b) Gene
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albuminuria induced by ADR (10mg/kg body weight) in BALB/c mice. (d–f) Exogenous HGF expression ameliorated podocyte injury (as
defined by Wilm’s tumor 1 (WT1) and nephrin loss) in mice. Representative micrographs of WT1 and nephrin staining (d) and quantitative
determination of WT1-positive cell number (e) and injury score in different groups (f) are given. *Po0.05 versus vehicle controls; wPo0.05
versus pcDNA3 controls (n¼ 4–11). (g) Exogenous HGF did not significantly ameliorate albuminuria in podo-met/ mice after ADR injury.
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promoter begins to express in podocytes during late capillary
loop stage of glomerular development in the newborn mice.32
Therefore, it remains to be determined whether HGF/c-met
signaling has a role in mediating the initial differentiation of
podocytes during early kidney development.
This study provides a clear in vivo evidence for a critical
role of HGF/c-met signaling in preventing podocyte
dysfunction and apoptosis after injury. Both loss- and gain-
of-function strategies indicate that HGF specifically acts on
podocytes to protect against dedifferentiation and apoptosis
triggered by injurious stimuli. Although recent studies point
to alterations in glomerular endothelium at 6 days after ADR
injection,33 the cause–effect relationship of these endothelial
lesions with proteinuria remains uncertain in this model.
Podocyte dysfunction occurs early in ADR nephropathy,34 in
which albuminuria is eminent in 1–3 days (Figure 2). Indeed,
exogenous HGF only ameliorates albuminuria in podo-
metþ /þ mice, but not in podo-met/ mice (Figure 5g),
supporting a direct and predominant role of podocyte-
specific c-met activation in conferring HGF renoprotection
against albuminuria in this model. Adriamycin is well known
to specifically damage podocytes in the glomeruli and to
trigger kidney lesions characterized by proteinuria and
glomerulosclerosis,22 though its pathogenic mechanism
in vivo remains poorly understood. We show here that
ADR induces WT1 and nephrin loss in vivo, suggesting that
podocyte dedifferentiation could be attributable to the
development of albuminuria. Given that podocyte apoptosis
is an extremely rare event (Figure 4), it seems unlikely that
podocyte depletion is the initial cause that results in the onset
of albuminuria in this model. In this context, downregulation
of WT1 gene and suppression of nephrin expression seem to
be two major pathogenic alterations in glomerular podocytes
in vivo after ADR administration that undoubtedly leads to
podocyte dysfunction. Indeed, low dose of ADR (2 mg/ml)
also suppresses bothWT1 and nephrin expression in cultured
mouse podocytes in vitro (Figure 7). The observation that
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HGF preserves WT1 and nephrin in podocytes both in vivo
and in vitro suggests that this signaling is able to specifically
target the key pathogenic events in ADR nephropathy.
Notably, in addition to a reduced mRNA expression, nephrin
loss could also result from a shedding of its protein from
the cell surface due to protease-mediated cleavage and
cytoskeleton redistribution.35 It remains to be determined
whether HGF also protects podocytes from nephrin shedding
after injury.
WT1 is a key transcription factor that has an essential
role in early kidney development. In adult kidney, WT1
expression is restricted to mature podocytes, and is thought
to be crucial in trans-activating multiple podocyte-specific
genes, including nephrin and podocalyxin. Along this line,
downregulation of WT1 expression by ADR could be an
important pathway leading to suppression of podocyte-
specific genes, thereby causing podocyte dysfunction and the
onset of proteinuria. This idea is substantiated by the
observation that nephrin is downregulated in podocytes by
ADR. It should be pointed out that HGF alone seems to
have the tendency to inhibit nephrin expression in cultured
podocytes (Figure 7), consistent with a previous report.36
However, this slight inhibition of nephrin expression by
HGF treatment alone in cultured podocytes in vitro is
unlikely relevant to physiological conditions in vivo, as
previous studies show that sustained expression of exogenous
HGF for a long period of time (8 weeks) in mice does not
cause any impairment of glomerular filtration and kidney
function.37 Importantly, concomitant incubation with HGF
and ADR, a situation that closely resembles HGF adminis-
tration in the pathological setting, is able to upregulate and
preserve nephrin expression.
Severe and/or sustained injury undoubtedly causes
podocyte apoptosis that eventually leads to podocyte
depletion and glomerulosclerosis in the kidney.16,38 Studies
in animal models have established that podocyte numbers
and density have a decisive role in the genesis of proteinuria
and glomerulosclerosis.12,38 In that regard, the ability of HGF
in promoting cell survival could also have a role in protecting
podocyte after injury.39,40 Indeed, this study demonstrates
that HGF is able to protect cultured podocytes against
apoptosis induced by a lethal dose of ADR (20 mg/ml), a
concentration that is 10-fold higher than that induces
podocyte dedifferentiation, as manifested by WT1 and
nephrin suppression. Even at that high concentration of
ADR, HGF is able to protect podocytes from undergoing
apoptotic cell death, as evidenced by caspas-3 activation and
terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling staining. This cytoprotective effect of HGF
against lethal dose of ADR is largely mediated by PI3K/Akt
pathway, as blockade of Akt activation, but not of Erk-1/2,
abolishes the ability of HGF to inhibit caspase-3 activation in
podocytes. Notably, HGF seems to be more potent in
protecting human podocytes from apoptosis induced
by ADR, in comparison with their mouse counterparts
(Figure 8). This probably reflects that human HGF
preferentially works on human podocytes, despite a high
degree of homology between human and mouse HGF
proteins.41 Accordingly, as the HGF gene injected into mice
is of human origin, the effects of exogenous HGF in vivo are
probably underestimated in this study.
In summary, we have demonstrated that HGF/c-met
signaling has an important role in protecting podocytes from
injury. HGF not only prevents podocytes from dedifferentia-
tion and dysfunction after sublethal injury, but also protects
podocytes against apoptosis after more severe insult. Our
studies suggest that protection of podocyte from injury and
depletion by exogenous HGF could be an effective way to
prevent proteinuria and glomerulosclerosis under pathologi-
cal conditions.
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MATERIALS AND METHODS
Generation of the podocyte-specific c-met knockout mice and
genotyping
The c-met-floxed mice were created by homologous recombination
using a c-met gene fragment with loxP sites flanking exon 16, as
described previously,31,42 and kindly provided by Dr Snorri
S. Thorgeirsson (National Cancer Institute, NIH, Bethesda, MD,
USA). Transgenic mice expressing Cre recombinase under the
control of a 2.5-kb fragment of the human podocin promoter (2.5P-
Cre mice) are reported elsewhere.32 By mating c-met-floxed mice
with podocin-Cre transgenic mice, mice that were heterozygous for
the c-met-floxed allele were generated (genotype: c-metfl/þ , Creþ /
). These mice were crossbred to inactivate both c-met alleles by
Cre-mediated excision, thereby creating conditional knockout
mice in which c-met gene was specifically disrupted in glomerular
podocytes (genotype: c-metfl/fl, Creþ /). The breeding protocol also
generated heterozygous littermates (genotype: c-metfl/þ , Creþ /),
and wild type and several groups with different genotypes (c-metfl/fl,
Cre/; c-metfl/þ , Cre/; c-metþ /þ , Creþ /). Polymerase chain
reaction was used for c-met loxP and Cre genotyping. All mice with
ages between 1–3 months were used in the study except otherwise
indicated. Littermates with genotypes (c-metfl/fl, Cre/) were used
as podo-metþ /þ controls throughout the experiments. Experi-
mental protocols for animals were approved by the Institutional
Animal Care and Use Committee at the University of Pittsburgh.
Animal models of podocyte injury and proteinuria
Mouse model for podocyte injury and proteinuria was established
by intravenous injection of ADR.22 Different genetic backgrounds
and strains of mice displayed significant divergences in response to
ADR injury. All transgenic mice with C57BL/6J or mixed back-
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Figure 9 |Hepatocyte growth factor (HGF) prevents podocyte apoptosis induced by adriamycin (ADR) in vitro. Human podocytes
were treated with a lethal dose of ADR (20 mg/ml) in the absence or presence of HGF (20 ng/ml) for 12 h. (a) Representative micrographs
of phase-contrast, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining and immunostaining for
cleaved caspase-3. (b) Quantitative data of the detached cells after various treatments as indicated. (c) Quantitative data showing the
TUNEL-positive cells after various treatments as indicated. (d) Quantitative data showing the cleaved caspase-3-positive cells after various
treatments as indicated. *Po0.05 versus controls; wPo0.05 versus ADR alone (n¼ 4).
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grounds were injected with a high dose of ADR protocol (25mg/kg
body weight),34 whereas BALB/c mice were sensitive to and only
received a low dose of the drug (10mg/kg body weight). Briefly,
podo-met/ mice and their control podo-metþ /þ littermates were
injected with ADR (doxorubicin hydrochloride; Sigma, St Louis,
MO, USA) at the dosage of 25mg/kg body weight in saline solution
through tail vein. All male BALB/c mice weighing 20–22 g were
obtained from Harlan Sprague–Dawley (Indianapolis, IN, USA), and
injected through the tail vein with ADR at 10mg/kg body weight. At
different time points after ADR injection, mice were killed. Urine,
kidney tissue and glomeruli were collected. For introducing
exogenous HGF in vivo, mice were administrated with HGF
expression plasmid (pCMV-HGF) at 1mg/kg by a hydrodynamic-
based gene transfer technique through rapid injection of a large
volume of DNA solution through the tail vein, as described
previously.8,25,37 At 16 h after plasmid injection, mice were injected
with ADR through tail vein, and killed at day 4. Urine and kidney
samples were collected. Mouse backgrounds and ADR protocol used
in this study are listed in Table 1.
Urinary albumin and creatinine assay
Urine albumin level was measured by using a mouse Albumin ELISA
Quantification kit, according to the manufacturer’s protocol (Bethyl
Laboratories, Montgomery, TX, USA). Urine creatinine was
determined by a routine procedure as described previously.43
Urinary proteins were also analyzed by sodium dodecyl sulfate–
polyacrylamine gel electrophoresis after normalization to urinary
creatinine. After separation by sodium dodecyl sulfate–polyacryla-
mine gel electrophoresis, urine proteins were stained with
Coomassie blue R-250.
Immunofluorescent staining and confocal microscopy
Kidney cryosections were fixed with 3.7% paraformalin for 15min
at room temperature. After blocking with 10% donkey serum for
30min, slides were immunostained with primary antibodies against
phospho-specific Erk-1/2 (Thr202/Tyr204; cat. no. 4370; Cell
Signaling Technology, Danvers, MA, USA) and nephrin (Progen,
Heidelberg, Germany), respectively. Slides were viewed under a
Leica TCS-SL confocal microscope (Bannockburn, IL, USA).43
For determination of the podocyte injury, as defined by nephrin
loss and altered distribution, a semiquantitative scoring method
was used. Score 0 represents no lesion, whereas 1, 2, 3, and 4
represent the nephrin loss and altered distribution, involving
o25%, 25–50%, 50–75%, and 475% of the glomerular tuft
area, respectively. At least five randomly chosen glomeruli were
evaluated for each mouse and an average composite score was
calculated. Paraffin-embedded mouse kidney sections (3mm thick-
ness) were prepared by a routine procedure. Immunohistochemical
staining for WT1 (sc-192; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and cleaved caspase-3 (cat. no. 9661; Cell Signaling
Technology) was performed using a routine protocol as described
previously.43,44
Glomerular isolation
Glomerular isolation was performed according to the method
described elsewhere.43,45 Briefly, mice were anesthetized by intraper-
itoneal injection of pentobarbital (50mg/kg) and perfused, through
the abdominal artery, with 8 107 Dynabeads M-450 (Dynal
Biotech ASA, Oslo, Norway) diluted in 5ml of phosphate buffered
saline. After perfusion, the kidneys were removed and cut into
1-mm3 pieces and digested in collagenase A (1mg/ml) at 37 1C for
30min with gentle shaking. The tissue was then pressed gently
through a 100-mm cell strainer (BD Falcon, Bedford, MA, USA).
Glomeruli-containing Dynabeads were then gathered by using a
magnetic particle concentrator. The isolated glomeruli were washed
three times with cold phosphate buffered saline and used for
Table 1 |Mouse model and ADR protocol used in this study
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ADR protocol
(mg/kg body
weight)
Albuminuriaa
(mg/mg Ucr.)
Figures
in this
study
Podo-met+/+ and podo-met/
(with mixed backgrounds)
25 2–6 1–4, 5g
BALB/c 10 12 5(a–f), 6
Abbreviation: ADR, adriamycin.
aDenotes typical urinary albuminuria levels at 3 days after ADR injection.
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Figure 10 |Hepatocyte growth factor (HGF) inhibits adriamycin (ADR)-induced caspase-3 cleavage through the phosphoinositide
3-kinase (PI3K)/Akt signal pathway. (a and b) Western blot analysis shows that HGF induced Akt (a) and Erk-1/2 (b) phosphorylation and
activation in human podocytes. Cell lysates were immunoblotted with specific antibodies against phospho-specific Akt and total Akt (a),
or phospho-specific Erk1/2 and glyceraldehyde 3 phosphate dehydrogenase (GAPDH) (b). PI3K inhibitor (wortmannin, 10 nM)
or Mek1 inhibitor (PD98059, 10 mM) effectively blocked the HGF-induced Akt and Erk-1/2 activation, respectively. (c and d) Blockade of
Akt activation by wortmannin, but not Erk-1/2 activation by PD98059, abolished the antiapoptotic effect of HGF in both mouse (c) and
human podocytes (d). Cell lysates were immunoblotted with specific antibodies against pro-caspase-3 or cleaved caspase-3, respectively.
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subsequent studies. The purity of the isolated glomeruli reached to
more than 95% by this method.
Western blot analysis
The isolated glomeruli were pooled and lysed with radioimmuno-
precipitation assay buffer containing 1% NP-40, 0.1% sodium
dodecyl sulfate, 100 mg/ml phenylmethylsulfonyl fluoride, 1%
protease inhibitor cocktail, and 1% phosphatase I and II inhibitor
cocktail (Sigma) in phosphate buffered saline on ice. The super-
natants were collected after centrifugation at 13,000 g at 4 1C for
20min. Cultured podocytes were lysed in sodium dodecyl sulfate
sample buffer. Protein expression was detected by western blot
analysis as described previously.43 The primary antibodies used
were as follows: anti-WT1 (Santa Cruz Biotechnology); anti-c-met
(cat. no. 3127), anti-cleaved caspase-3, anti-phospho-specific Akt
(Ser473; cat no. 4060) and total Akt (cat. no. 9272), anti-phopsho-
specific Erk-1/2 (cat. no. 4370;Cell Signaling Technology); anti-
glyceraldehyde-3-phosphate dehydrogenase (cat. no. 4300; Ambion),
anti-procaspase-3 (sc-7148; Santa Cruz Biotechnology), and anti-a-
tubulin (cat. no. T9026; Sigma).
Electron microscopy
Electron microscopy of kidney samples was carried out by routine
procedures as described previously.43 Briefly, mouse kidneys were
perfusion fixed with 2.5% glutaraldehyde in phosphate buffered
saline by left cardiac ventricular injection and post-fixed in aqueous
1% OsO4. Specimens were dehydrated through an ethanol series,
infiltrated in a 1:1 mixture of propylene oxide/Polybed 812 epoxy
resin (Polysciences, Warrington, PA, USA), and then embedded.
Ultrathin sections were stained with 2% uranyl acetate, followed by
1% lead citrate. Sections were observed and photographed using a
JEOL JEM 1210 transmission electron microscope (Peabody,
MA, USA).
Cell culture and treatment
The conditionally immortalized mouse podocyte cell line was kindly
provided by Dr Peter Mundel (Mount Sinai School of Medicine,
New York, NY, USA) and described previously.46 Immortalized
human podocytes were described previously.47 Cells were cultured at
33 1C in RPMI-1640 medium supplemented with 10% fetal bovine
serum and recombinant interferon-g (Invitrogen, Carlsbad, CA,
USA). To induce differentiation, podocytes were grown under
nonpermissive conditions at 37 1C in the absence of interferon-g.
After serum starvation for 16 h, cells were treated with ADR in the
absence or presence of human recombinant HGF (R&D Systems,
Minneapolis, MN, USA) for various periods of time as indicated. In
some experiments, cells were pretreated with either various
inhibitors at given concentrations or vehicle (0.1% dimethylsulf-
oxide) 0.5 h before incubation with HGF. Wortmannin (PI3K
inhibitor) and PD98059 (Mek1 inhibitor) were purchased from
Calbiochem (La Jolla, CA, USA).
RNA extraction and reverse transcriptase–PCR
For determination of nephrin mRNA expression, a semi-quantitative
reverse transcriptase–PCR was used. Total RNA isolation and reverse
transcriptase–PCR amplification of nephrin mRNA were carried out
using the procedures described previously.17 Briefly, the first-strand
complementary DNA synthesis was carried out using a Reverse
Transcription System kit, according to the instructions of the
manufacturer (Promega, Madison, WI, USA). Polymerase chain
reaction amplification was performed using HotStar Taq Master Mix
Kit (Qiagen, Valencia, CA, USA). The sequences of nephrin and
b-actin primer pairs have been described previously.17 After
quantifying bands using densitometry, the relative steady-state level
of mRNAwas calculated and compared after normalizing to b-actin.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling staining
Apoptotic cell death was determined using terminal deoxynucleo-
tidyl transferase-mediated dUTP nick-end labeling staining using
Apoptosis Detection System (Promega), as previously reported.43
Statistical analyses
Statistical analysis of the data was performed using SigmaStat
software (Jandel Scientific, San Rafael, CA, USA). Comparison
between groups was made using one-way analysis of variance,
followed by the Student–Newman–Keuls test. Po0.05 was consid-
ered statistically significant.
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